RSS-Feed abonnieren
DOI: 10.1055/a-2768-2882
Postoperative Recurrence of ROS1-Rearranged Lung Adenocarcinoma: A Case Series
Autor*innen
Abstract
Postoperative recurrence of c-ros oncogene 1 (ROS1)-rearranged non-small cell lung cancer is rarely reported, and the role of tyrosine kinase inhibitors (TKIs) remains unclear. We retrospectively reviewed four patients with completely resected ROS1-positive lung adenocarcinoma who developed recurrence, three receiving crizotinib. The median disease-free interval was 33.4 months, and the median overall survival from postoperative recurrence and initial surgery was 40.7 and 71.2 months, respectively. Brain metastases were the most common initial recurrence site (75%). Crizotinib showed limited efficacy with a median progression-free survival of 3.5 months. These findings highlight indolent disease behavior but limited TKI benefit, supporting the need for adjuvant trials.
Keywords
c-ros oncogene 1 rearrangements - anaplastic lymphoma kinase inhibitor - postoperative recurrence - lung adenocarcinomaContributors' Statement
R.M. contributed to conceptualization, data curation, writing–original draft. R.N. and R.S. contributed to data curation. M.H. contributed to conceptualization, data curation, writing–review and editing.
Publikationsverlauf
Eingereicht: 17. September 2025
Angenommen: 08. Dezember 2025
Accepted Manuscript online:
12. Dezember 2025
Artikel online veröffentlicht:
23. Dezember 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Accessed February 2, 2025 at: www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
- 2 Japanese Lung Cancer Society. Clinical Practice Guidelines in Lung Cancer, 2024 Edition. Accessed February 2, 2025; available at: www.haigan.gr.jp/publication/guideline/examination/2024/
- 3 Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat Rev Clin Oncol 2021; 18 (01) 35-55
- 4 Nishino M, Soejima K, Mitsudomi T. Brain metastases in oncogene-driven non-small cell lung cancer. Transl Lung Cancer Res 2019; 8 (Suppl. 03) S298-S307